Amarpreet Sawhney

Amar is the President and CEO of Octux, Inc. a company focused on unmet needs in ophthalmic surgical wound closure and drug delivery. Previously, he was Founder and CEO of Confluent Surgical (acquired by Covidien), a biosurgery company. He was Chairman of marketRx (acquired by Cognizant), a provider of pharmaceutical marketing and sales analytics and intelligence. Before Confluent, Amar was the technology founder of Focal, Inc. (acquired by Genzyme). Amar’s innovations are the subject of almost 100 issued and pending patents. He is a board member of Soteira, Square One and TiE Boston. He is a board member and founder of Access Closure, Octux, Augmenix, and Incept LLC. Amar volunteers his time with entrepreneurial organizations including TiE Boston, MassMedic, and the E&Y Entrepreneur of the Year program. Amar and Confluent have been recognized with awards including MassMedic best startup company award, Frost and Sullivan Product innovation award, MIT Global Indus Technovators Award, E&Y regional entrepreneur of the year award, Mass High Tech All Star award, and University of Texas Outstanding Young Engineering Graduate award. Amar holds a Ph.D. and M.S. in Chemical Engineering from the University of Texas at Austin and a B.Tech. in Chemical Engineering from the Indian Institute of Technology, New Delhi.